Alternative Modulation of Protein-protein Interactions by Small Molecules

Overview

Journal Curr Opin Biotechnol

Publisher Elsevier

Specialty Biotechnology

Date 2015 May 4

PMID 25935873

Citations 30

Authors

Gerhard Fischer

Maxim Rossmann

Marko Hyvonen

Affiliations

Soon will be listed here.

Abstract

Protein-protein interactions (PPI) have become increasingly popular drug targets, with a number of promising compounds currently in clinical trials. Recent research shows, that PPIs can be modulated in more ways than direct inhibition, where novel non-competitive modes of action promise a solution for the difficult nature of PPI drug discovery. Here, we review recently discovered PPI modulators in light of their mode of action and categorise them as disrupting versus stabilising, orthosteric versus allosteric and by their ability to affect the proteins' dynamics. We also give recent examples of compounds successful in the clinic, analyse their physicochemical properties and discuss how to overcome the hurdles in discovering alternative modes of modulation.

Citing Articles

New insights into protein-protein interaction modulators in drug discovery and therapeutic advance.

Nada H, Choi Y, Kim S, Jeong K, Meanwell N, Lee K Signal Transduct Target Ther. 2024; 9(1):341.

PMID: 39638817 PMC: 11621763. DOI: 10.1038/s41392-024-02036-3.

Allosteric nanobodies to study the interactions between SOS1 and RAS.

Fischer B, Uchanski T, Sheryazdanova A, Gonzalez S, Volkov A, Brosens E Nat Commun. 2024; 15(1):6214.

PMID: 39043660 PMC: 11266648. DOI: 10.1038/s41467-024-50349-2.

The state of the art in secondary pharmacology and its impact on the safety of new medicines.

Brennan R, Jenkinson S, Brown A, Delaunois A, Dumotier B, Pannirselvam M Nat Rev Drug Discov. 2024; 23(7):525-545.

PMID: 38773351 DOI: 10.1038/s41573-024-00942-3.

Targeting protein-protein interaction interfaces with antiviral N protein inhibitor in SARS-CoV-2.

Hong J, Lin S, Kehn-Hall K, Zhang K, Luo S, Wu H Biophys J. 2024; 123(4):478-488.

PMID: 38234090 PMC: 10912909. DOI: 10.1016/j.bpj.2024.01.013.

Small molecules targeting protein-protein interactions for cancer therapy.

Wu D, Li Y, Zheng L, Xiao H, Ouyang L, Wang G Acta Pharm Sin B. 2023; 13(10):4060-4088.

PMID: 37799384 PMC: 10547922. DOI: 10.1016/j.apsb.2023.05.035.

References

Lee C, Lu W, Michel J, Goehring A, Du J, Song X . NMDA receptor structures reveal subunit arrangement and pore architecture. Nature. 2014; 511(7508):191-7. PMC: 4263351. DOI: 10.1038/nature13548. View

Higueruelo A, Schreyer A, Bickerton G, Pitt W, Groom C, Blundell T . Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem Biol Drug Des. 2009; 74(5):457-67. DOI: 10.1111/j.1747-0285.2009.00889.x. View

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

Giordanetto F, Schafer A, Ottmann C . Stabilization of protein-protein interactions by small molecules. Drug Discov Today. 2014; 19(11):1812-1821. DOI: 10.1016/j.drudis.2014.08.005. View

Hammoudeh D, Follis A, Prochownik E, Metallo S . Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc. 2009; 131(21):7390-401. DOI: 10.1021/ja900616b. View

Huang H, Ceccarelli D, Orlicky S, St-Cyr D, Ziemba A, Garg P . E2 enzyme inhibition by stabilization of a low-affinity interface with ubiquitin. Nat Chem Biol. 2013; 10(2):156-163. PMC: 3905752. DOI: 10.1038/nchembio.1412. View

Arkin M, Tang Y, Wells J . Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol. 2014; 21(9):1102-14. PMC: 4179228. DOI: 10.1016/j.chembiol.2014.09.001. View

Thiel P, Kaiser M, Ottmann C . Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?. Angew Chem Int Ed Engl. 2012; 51(9):2012-8. DOI: 10.1002/anie.201107616. View

You J, Li Q, Wu C, Kim J, Ottinger M, Howley P . Regulation of aurora B expression by the bromodomain protein Brd4. Mol Cell Biol. 2009; 29(18):5094-103. PMC: 2738288. DOI: 10.1128/MCB.00299-09. View

10.

Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P . RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A. 2013; 110(49):19754-9. PMC: 3856850. DOI: 10.1073/pnas.1310658110. View

11.

Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clercq E, Debyser Z . LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem. 2003; 278(35):33528-39. DOI: 10.1074/jbc.M303594200. View

12.

Schubbert S, Shannon K, Bollag G . Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007; 7(4):295-308. DOI: 10.1038/nrc2109. View

13.

Silvian L, Enyedy I, Kumaravel G . Inhibitors of protein-protein interactions: new methodologies to tackle this challenge. Drug Discov Today Technol. 2014; 10(4):e509-15. DOI: 10.1016/j.ddtec.2012.10.004. View

14.

Merdanovic M, Monig T, Ehrmann M, Kaiser M . Diversity of allosteric regulation in proteases. ACS Chem Biol. 2012; 8(1):19-26. DOI: 10.1021/cb3005935. View

15.

Yin X, Giap C, Lazo J, Prochownik E . Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene. 2003; 22(40):6151-9. DOI: 10.1038/sj.onc.1206641. View

16.

Sun Q, Burke J, Phan J, Burns M, Olejniczak E, Waterson A . Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl. 2012; 51(25):6140-3. PMC: 3620661. DOI: 10.1002/anie.201201358. View

17.

Bulawa C, Connelly S, Devit M, Wang L, Weigel C, Fleming J . Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012; 109(24):9629-34. PMC: 3386102. DOI: 10.1073/pnas.1121005109. View

18.

Sledz P, Stubbs C, Lang S, Yang Y, McKenzie G, Venkitaraman A . From crystal packing to molecular recognition: prediction and discovery of a binding site on the surface of polo-like kinase 1. Angew Chem Int Ed Engl. 2011; 50(17):4003-6. PMC: 3555362. DOI: 10.1002/anie.201008019. View

19.

Kessl J, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, Feng L . Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem. 2012; 287(20):16801-11. PMC: 3351293. DOI: 10.1074/jbc.M112.354373. View

20.

Sondermann H, Soisson S, Boykevisch S, Yang S, Bar-Sagi D, Kuriyan J . Structural analysis of autoinhibition in the Ras activator Son of sevenless. Cell. 2004; 119(3):393-405. DOI: 10.1016/j.cell.2004.10.005. View